RU2505604C2 - Профилактическая вакцина против вич, основанная на вич-специфических антителах - Google Patents

Профилактическая вакцина против вич, основанная на вич-специфических антителах Download PDF

Info

Publication number
RU2505604C2
RU2505604C2 RU2010116849/10A RU2010116849A RU2505604C2 RU 2505604 C2 RU2505604 C2 RU 2505604C2 RU 2010116849/10 A RU2010116849/10 A RU 2010116849/10A RU 2010116849 A RU2010116849 A RU 2010116849A RU 2505604 C2 RU2505604 C2 RU 2505604C2
Authority
RU
Russia
Prior art keywords
hiv
peptides
recombinant
cag
antibodies
Prior art date
Application number
RU2010116849/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010116849A (ru
Inventor
Елена Ю. Филинова
Original Assignee
Текнолоджи Интеграл Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Текнолоджи Интеграл Лтд. filed Critical Текнолоджи Интеграл Лтд.
Publication of RU2010116849A publication Critical patent/RU2010116849A/ru
Application granted granted Critical
Publication of RU2505604C2 publication Critical patent/RU2505604C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010116849/10A 2007-10-09 2008-10-09 Профилактическая вакцина против вич, основанная на вич-специфических антителах RU2505604C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97853607P 2007-10-09 2007-10-09
US60/978,536 2007-10-09
PCT/EP2008/008544 WO2009046984A1 (en) 2007-10-09 2008-10-09 Hiv preventive vaccine based on hiv specific antibodies

Publications (2)

Publication Number Publication Date
RU2010116849A RU2010116849A (ru) 2011-11-20
RU2505604C2 true RU2505604C2 (ru) 2014-01-27

Family

ID=40342551

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010116849/10A RU2505604C2 (ru) 2007-10-09 2008-10-09 Профилактическая вакцина против вич, основанная на вич-специфических антителах

Country Status (12)

Country Link
US (1) US20100215695A1 (enExample)
EP (1) EP2205736B1 (enExample)
JP (1) JP2010540674A (enExample)
KR (1) KR20100098597A (enExample)
CN (1) CN101970659A (enExample)
AU (1) AU2008309940B2 (enExample)
BR (1) BRPI0818354A2 (enExample)
CA (1) CA2701948A1 (enExample)
MX (1) MX2010003762A (enExample)
RU (1) RU2505604C2 (enExample)
WO (1) WO2009046984A1 (enExample)
ZA (1) ZA201002445B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016076762A1 (ru) * 2014-11-11 2016-05-19 Открытое акционерное общество "Фармсинтез" Композиция и лекарственная форма для лечения и профилактики вич инфекции и способ ее получения
RU2792843C2 (ru) * 2017-07-12 2023-03-27 Ноуском Аг (Nouscom Ag) Универсальная вакцина на основе общих опухолевых неоантигенов для предупреждения и лечения форм рака с микросателлитной нестабильностью (msi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422618A1 (en) * 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN102190726B (zh) * 2011-03-30 2013-03-27 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用
HK1200359A1 (zh) * 2011-09-17 2015-08-07 源道隆（苏州）医学科技有限公司 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导
US10660951B2 (en) 2012-09-17 2020-05-26 Zhiwei Allen Wu Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
ES2959642T3 (es) * 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
EP3464348A4 (en) * 2016-05-25 2020-01-22 University Of Maryland, Baltimore METHOD FOR PRODUCING ACTIVE ANTIBODIES FROM BIOLOGICAL LIQUIDS
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
WO2018237357A1 (en) 2017-06-22 2018-12-27 University Of Maryland, Baltimore HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
IT202100004160A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Cellula ospite di leishmania
IT202100004172A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Nuova composizione

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRETON M. et al. "A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection", J Gen Virol (2007), 88: 217-225. *
BURTON D. et al. "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals", Proc. Nati. Acad. Sci. USA (1991), 88: 10134-10137. *
CHOUDHRY V. et al. "Cross-Reactive HIV-1 Neutralizing Monoclonal Antibodies Selected by Screening of an Immune Human Phage Library against an Envelope Glycoprotein (gp140) Isolated from a Patient (R2) with Broadly HIV-1 Neutralizing Antibodies", Virology (2007), 363(1): 79-90. *
LUNDIN K. et al. "Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry", Immunology (1996), 89: 579-586. *
PARREN P. et al. "In Vitro Antigen Challenge of Human Antibody Libraries for Vaccine Evaluation: the Human Immunodeficiency Virus Type 1 Envelope", Journal of Virology, (1996), 70(12): 9046-9050. *
PARREN P. et al. "In Vitro Antigen Challenge of Human Antibody Libraries for Vaccine Evaluation: the Human Immunodeficiency Virus Type 1 Envelope", Journal of Virology, (1996), 70(12): 9046-9050. BRETON M. et al. "A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection", J Gen Virol (2007), 88: 217-225. WANG X. et al. "Construction of human combinatorial antibody library and screening of monoclonal antibody Fabs to human immunodeficiency virus type 1", Chinese Science Bulletin (1999), 44: 352-356. LUNDIN K. et al. "Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry", Immunology (1996), 89: 579-586. BURTON D. et al. "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries *
WANG X. et al. "Construction of human combinatorial antibody library and screening of monoclonal antibody Fabs to human immunodeficiency virus type 1", Chinese Science Bulletin (1999), 44: 352-356. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016076762A1 (ru) * 2014-11-11 2016-05-19 Открытое акционерное общество "Фармсинтез" Композиция и лекарственная форма для лечения и профилактики вич инфекции и способ ее получения
RU2792843C2 (ru) * 2017-07-12 2023-03-27 Ноуском Аг (Nouscom Ag) Универсальная вакцина на основе общих опухолевых неоантигенов для предупреждения и лечения форм рака с микросателлитной нестабильностью (msi)

Also Published As

Publication number Publication date
BRPI0818354A2 (pt) 2017-05-16
KR20100098597A (ko) 2010-09-08
AU2008309940B2 (en) 2013-11-14
MX2010003762A (es) 2010-09-10
EP2205736A1 (en) 2010-07-14
EP2205736B1 (en) 2014-04-02
JP2010540674A (ja) 2010-12-24
AU2008309940A1 (en) 2009-04-16
WO2009046984A1 (en) 2009-04-16
ZA201002445B (en) 2011-03-30
CA2701948A1 (en) 2009-04-16
US20100215695A1 (en) 2010-08-26
CN101970659A (zh) 2011-02-09
RU2010116849A (ru) 2011-11-20

Similar Documents

Publication Publication Date Title
EP2205736B1 (en) A method for producing an HIV immunogenic composition based on HIV-specific antibodes
ES2251734T3 (es) Genes sinteticos de hiv.
US20230151385A1 (en) Selectable marker proteins, expression vectors, engineered cells and extracellular vesicles for the production of virus-like particles for therapeutic and prophylactic applications
FI113476B (fi) Menetelmä yhdistelmäretroviruksen valmistamiseksi
US20030229214A1 (en) Vaccines comprising synthetic genes
CA2258568A1 (en) Vaccines comprising synthetic genes
JPH09510097A (ja) 同調的インビボ遺伝子発現
KR20020013537A (ko) 면역 반응을 유발하는 항원을 동정하기 위한 조성과 방법
US9402917B2 (en) Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions
JP2002508940A (ja) ヒト化抗体およびその使用
US8754015B2 (en) Modified phage for displaying post-translationally modified proteins and uses thereof
JP2004525931A (ja) バクテリオファージによって仲介される免疫化方法
HK1151554A (en) Hiv preventive vaccine based on hiv specific antibodies
CN114685683A (zh) 靶向gd2的car-t细胞及其制备和应用
CN112876566A (zh) 一种cd3特异性慢病毒的构建及其应用
WO2010051215A1 (en) Methods for making hiv vaccines and related compositions
CN101588813A (zh) 诱导人类免疫缺陷病毒的中和抗体的方法
US20030087225A1 (en) Synthetic HIV genes
MXPA98006842A (en) Synthetic genes of
Ward Novel fusion protein-expressing lentiviral vectors ameliorate collagen induced arthritis
CA2245646A1 (en) Synthetic hiv genes

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151010